Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
Investor Presentations
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
Investor Presentations
Filter by Year:
2025
2024
2023
2022
2021
15-Nov-2024
Investor presentation, 15 November 2024
7-Oct-2024
Investor webinar: Neuren continues PMS Phase 3 preparations following positive FDA meeting
19-Aug-2024
Investor roadshow presentation, 19 August 2024
9-Aug-2024
Investor webinar: NNZ-2591 Angelman syndrome Phase 2 trial top-line results
9-Aug-2024
NNZ-2591 Angelman top-line results presentation
29-May-2024
Corporate Presentation, 29 May 2024
28-May-2024
AGM webcast, 28 May 2024
28-May-2024
AGM Chair Address & CEO Presentation
27-May-2024
Investor webinar - Pitt Hopkins Phase 2 results, 27 May 2024
27-May-2024
Pitt Hopkins Phase 2 results presentation, 27 May 2024
1
2
Next